Skip to main content
Premium Trial:

Request an Annual Quote

People in the News: Douglas Williams, Barry Greene, Stanley Crooke, Yitzhak Peterburg

Premium

Regulus Therapeutics has appointed Douglas Williams to its board of directors.

Williams is currently executive vice president of research and development at Biogen Idec, a Regulus collaborator that recently purchased a $5 million convertible note from the firm.

Concurrent with Williams' appointment, Regulus said that directors Barry Greene and Stanley Crooke have stepped down. Greene is president and COO of Alnylam Pharmaceuticals and Crooke is chairman and CEO of Isis Pharmaceuticals, which created Regulus as a joint venture.


Rosetta Genomics has appointed Yitzhak Peterburg to its board of directors.

Peterburg has served on the boards of Teva Pharmaceuticals, and was president and CEO of Cellcom.

The Scan

Not as High as Hoped

The Associated Press says initial results from a trial of CureVac's SARS-CoV-2 vaccine suggests low effectiveness in preventing COVID-19.

Finding Freshwater DNA

A new research project plans to use eDNA sampling to analyze freshwater rivers across the world, the Guardian reports.

Rise in Payments

Kaiser Health News investigates the rise of payments made by medical device companies to surgeons that could be in violation of anti-kickback laws.

Nature Papers Present Ginkgo Biloba Genome Assembly, Collection of Polygenic Indexes, More

In Nature this week: a nearly complete Ginkgo biloba genome assembly, polygenic indexes for dozens of phenotypes, and more.